WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates. “The first quarter of 2026 materially strengthened Turn Therapeutics both operationally and financially,”…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
